Power Law company profile

Rhythm Pharmaceuticals

Biotech & Life Sciences · Boston, United States · Founded 2008 · IPO 2017 Unicorn

Rhythm Pharmaceuticals - Rhythm is developing peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders.

Valuation

$5.32B

Market cap · May/2026

Revenue

$194M

Latest reported FY

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026 $10B+ revenueThoroughbred · Power Law outcome

Investors

8 investors on Rhythm Pharmaceuticals's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 8 investors entered at this stage

Deerfield

Third Rock Ventures

Wellington Management

Pfizer Ventures

MPM BioImpact

NEA

OrbiMed

Ipsen

Global footprint

Where Rhythm Pharmaceuticals has talent and traffic

Workforce by country

17 countries with
team presence

🇺🇸 United States70%

🇳🇱 Netherlands8.9%

🇫🇷 France5.7%

🇬🇧 United Kingdom3.6%

🇩🇪 Germany2.9%

Top 5 of 17 shown

Web traffic by country

28K monthly visits
across markets

🇺🇸 United States65%

🇮🇳 India13.2%

🇨🇦 Canada6.1%

🇬🇧 United Kingdom5.7%

🇯🇵 Japan4.6%

Top 5 markets shown

Market sentiment

What the market is saying about Rhythm Pharmaceuticals

An AI-synthesized read of the highest-engagement posts about Rhythm Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Rhythm Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles